Antivitaminiques K, anticoagulants oraux directs : où est la vérité ?

Moustafa, 2015, Étude rétrospective concernant 73 patients traités par un anticoagulant oral direct admis consécutivement dans un service d’urgence, J Mal Vasc, 40, 1, 10.1016/j.jmv.2014.12.001 Wallentin, 2010, Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial, Lancet, 376, 975, 10.1016/S0140-6736(10)61194-4 Vasquez, 2016, Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis, Thromb Res, 138, 1, 10.1016/j.thromres.2015.12.013 Prochaska, 2015, Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service – results from the prospective, multi-center, observational cohort study thrombEVAL, BMC Med, 13, 14, 10.1186/s12916-015-0268-9 ANSM, 2014 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Wieloch, 2011, Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA, Eur Heart J, 32, 2282, 10.1093/eurheartj/ehr134 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 van Es, 2014, Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials, Blood, 124, 1968, 10.1182/blood-2014-04-571232 Cohen, 2016, Extended thromboprophylaxis with betrixaban in acutely ill medical patients, N Engl J Med, 375, 534, 10.1056/NEJMoa1601747 Albers, 2005, Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial, JAMA, 293, 690, 10.1001/jama.293.6.690 Eikelboom, 2015, Idarucizumab: the antidote for reversal of dabigatran, Circulation, 132, 2412, 10.1161/CIRCULATIONAHA.115.019628 Pollack, 2015, Idarucizumab for dabigatran reversal, N Engl J Med, 373, 511, 10.1056/NEJMoa1502000 Siegal, 2015, Andexanet alfa for the reversal of factor Xa inhibitor activity, N Engl J Med, 373, 2413, 10.1056/NEJMoa1510991 Godier, 2016, Hémorragie survenant chez un patient traité par un anticoagulant oral direct, J Mal Vasc, 41, 272, 10.1016/j.jmv.2016.05.008 Weitz, 2016, Urgent need to measure effects of direct oral anticoagulants, Circulation, 134, 186, 10.1161/CIRCULATIONAHA.116.022307 Tripodi, 2016, To measure or not to measure direct oral anticoagulants before surgery or invasive procedures, J Thromb Haemost, 14, 1325, 10.1111/jth.13344 Hohnloser, 2015, Dabigatran and myocardial infarction, Chest, 147, e70, 10.1378/chest.14-2534 Morimoto, 2015, Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: a network meta-analysis with the adjustment for the possible bias from open label studies, J Cardiol, 66, 466, 10.1016/j.jjcc.2015.05.018 Beyer-Westendorf, 2016, Vaginal bleeding and heavy menstrual bleeding during direct oral anti-Xa inhibitor therapy, Thromb Haemost, 115, 1234, 10.1160/TH15-11-0902 Kearon, 2016, Antithrombotic therapy for VTE disease, Chest, 149, 315, 10.1016/j.chest.2015.11.026 Konstantinides, 2014, ESC guidelines on the diagnosis and management of acute pulmonary embolism. Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC), Eur Heart J, 35, 3033, 10.1093/eurheartj/ehu283 Carrier, 2014, Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis, Thromb Res, 134, 1214, 10.1016/j.thromres.2014.09.039 Debourdeau, 2013, International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer, J Thromb Haemost, 11, 71, 10.1111/jth.12071 Simes, 2014, Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration, Circulation, 130, 1062, 10.1161/CIRCULATIONAHA.114.008828 Sobieraj, 2015, Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis, Thromb Res, 135, 888, 10.1016/j.thromres.2015.02.032 Albaladejo, 2014, Bon usage d’apixaban : que retenir pour la pratique, J Mal Vasc, 39, 409, 10.1016/j.jmv.2014.09.002 Weitz, 2015, Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study, Thromb Haemost, 114, 645, 10.1160/TH15-02-0131 Palareti, 2016, The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study, Thromb Haemost, 115, 1101, 10.1160/TH15-10-0830 Khetta, 2015, Quelle place pour les anticoagulants oraux directs en pratique hospitalière quotidienne ?, Rev Med Interne, 36, 813, 10.1016/j.revmed.2015.06.006 Bibbins-Domingo, 2016, Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement, Ann Intern Med, 164, 836, 10.7326/M16-0577 Büller, 2015, Factor XI antisense oligonucleotide for prevention of venous thrombosis, N Engl J Med, 372, 232, 10.1056/NEJMoa1405760 Whelihan, 2016, In vitro and in vivo characterization of a reversible synthetic heparin analog, Thromb Res, 138, 121, 10.1016/j.thromres.2015.12.007 Daly, 2015, Médicaments génériques et biosimilaires : une panacée ?, Rev Med Suisse, 11, 1909